CHICAGO – The investigational oral proteasome inhibitor MLN9708 showed hints of promise in multiple myeloma patients who are relapsed or refractory to treatment, investigators in a small phase I study reported here.
JUMP
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment